SYRE vs. IONS, OGN, BBIO, MDGL, CYTK, APLS, ALPN, NUVL, ALKS, and PRGO
Should you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include Ionis Pharmaceuticals (IONS), Organon & Co. (OGN), BridgeBio Pharma (BBIO), Madrigal Pharmaceuticals (MDGL), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), and Perrigo (PRGO). These companies are all part of the "pharmaceutical preparations" industry.
Spyre Therapeutics (NASDAQ:SYRE) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.
Spyre Therapeutics has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -49.49%. Spyre Therapeutics' return on equity of 0.00% beat Ionis Pharmaceuticals' return on equity.
Spyre Therapeutics has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
Spyre Therapeutics presently has a consensus price target of $43.17, indicating a potential upside of 23.12%. Ionis Pharmaceuticals has a consensus price target of $59.54, indicating a potential upside of 54.85%. Given Ionis Pharmaceuticals' higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Spyre Therapeutics.
Ionis Pharmaceuticals received 668 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 60.20% of users gave Ionis Pharmaceuticals an outperform vote.
80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 6.2% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Spyre Therapeutics and Spyre Therapeutics both had 2 articles in the media. Ionis Pharmaceuticals' average media sentiment score of 1.07 beat Spyre Therapeutics' score of 0.30 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.
Spyre Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.
Summary
Spyre Therapeutics and Ionis Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Spyre Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spyre Therapeutics Competitors List
Related Companies and Tools
